English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 909829      Online Users : 868
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/12686


    Title: Urate-lowering therapy exerts protective effects against hypertension development in patients with gout
    Authors: Lin, KH;Yen, FS;Li, HL;Wei, JCC;Hsu, CC;Yang, CC;Hwu, CM
    Contributors: Institute of Population Health Sciences
    Abstract: Many studies have demonstrated that hyperuricemia is associated with hypertension (HTN) development, but few studies have explored whether urate-lowering therapy (ULT), which reverses hyperuricemia, decreases the risk of incident HTN. In this retrospective cohort study, we compared the risk of incident HTN of gout patients between those undergoing and not undergoing ULT. Risks of new-onset diabetes mellitus (DM) and chronic kidney disease (CKD) were also examined. In total, 2712 gout patients from 2000 to 2012 were enrolled. Overall incidence rates of HTN, DM, and CKD were compared between 1356 patients undergoing ULT recipients and 1356 matched control patients. After adjustment for sex, age, area, comorbidities, and drugs used, the incidence rates of HTN were 4.8 and 3.0 per 100 person years for non-ULT and ULT patients, respectively. ULT patients had a lower adjusted hazard ratio (aHR) of HTN (aHR: 0.64, 95% confidence interval [CI]: 0.54-0.75, p < 0.001) than non-ULT patients. The lower risk of incident HTN after xanthine oxidase inhibitors exhibited a significant dose-response trend. ULT patients also had a lower risk of DM (aHR: 0.55, 95% CI: 0.43-0.70) than non-ULT patients. ULT patients exhibited no significant difference in CKD development (aHR: 1.04, 95% CI: 0.85-1.27) as compared with non-ULT patients. The present study revealed that ULT was associated with lower risks of incident HTN and DM, and the protective effect of xanthine oxidase inhibitors seemed to have a dose-response relationship.
    Date: 2021-04
    Relation: Journal of Human Hypertension. 2021 Apr;35(4):351-359.
    Link to: http://dx.doi.org/10.1038/s41371-020-0342-4
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0950-9240&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000530578000002
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85085137786
    Appears in Collections:[許志成] 期刊論文

    Files in This Item:

    File Description SizeFormat
    ISI000530578000002.pdf623KbAdobe PDF248View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback